Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: A review of the evidence

Clinical Infectious Diseases

Volumn 60, Issue 2, 2015, Pages 275-278

  Ehrhardt, Stephan ^a   Xie, Chan ^b   Guo, Nan ^a   Nelson, Kenrad ^a,c,d   Thio, Chloe L ^a,c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Department of International Health ^*  (United States)

Author keywords

breastfeeding; hepatitis B; lamivudine; tenofovir

Indexed keywords

LAMIVUDINE; TENOFOVIR DISOPROXIL; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PHOSPHONIC ACID DERIVATIVE;

AMNION FLUID; BREAST FEEDING; BREAST MILK; DRUG BIOAVAILABILITY; FEMALE; HEPATITIS B; HUMAN; MATERNAL SERUM; NONHUMAN; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REVIEW; UMBILICAL CORD; ANALOGS AND DERIVATIVES; DISEASE TRANSMISSION; NEWBORN; PREVENTION AND CONTROL; TRANSMISSION;

ADENINE; ANTI-HIV AGENTS; BREAST FEEDING; DISEASE TRANSMISSION, INFECTIOUS; FEMALE; HEPATITIS B; HUMANS; INFANT, NEWBORN; LAMIVUDINE; ORGANOPHOSPHONATES; PREGNANCY;

EID: 84924977749     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu798     Document Type: Review

References (29)

1. Franco E, Bagnato B, Marino MG, Meleleo C, Serino L, Zaratti L. Hepatitis B: epidemiology and prevention in developing countries. World J Hepatol 2012; 4:74-80.
2. Patton H, Tran TT. Management of hepatitis B during pregnancy. Nat Rev Gastroenterol Hepatol 2014; 11:402-9.
3. Greenup AJ, Tan PK, Nguyen V, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol 2014; 61:502-7.
4. Ter Borg MJ, Leemans WF, de Man RA, Janssen HLA. Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepat 2008; 15:37-41.
5. Yeh RF, Rezk NL, Kashuba AD, et al. Genital tract, cord blood, and am-niotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women. Antimicrob Agents Chemother 2009; 53:2367-74.
6. Moodley J, Moodley D, Pillay K, et al. Pharmacokinetics and antiretro-viral activity of lamivudine alone or when coadministered with zidovu-dine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis 1998; 178:1327-33.
7. Mandelbrot L, Peytavin G, Firtion G, Farinotti R. Maternal-fetal transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency virus-infected pregnant women. Am J Obstet Gynecol 2001; 184:153-8.
8. Chappuy H, Treluyer JM, Jullien V, et al. Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcrip-tase inhibitors in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2004; 48:4332-6.
9. Shapiro RL, Holland DT, Capparelli E, et al. Antiretroviral concentrations in breastfeeding infants of women in Botswana receiving antire-troviral treatment. J Infect Dis 2005; 192:720-7.
10. Giuliano M, Guidotti G, Andreotti M, et al. Triple antiretroviral prophylaxis administered during pregnancy and after delivery significantly reduces breast milk viral load: a study within the Drug Resource Enhancement Against AIDS and Malnutrition Program. J Acquir Immune Defic Syndr 2007; 44:286-91.
11. Corbett AH, Kayira D, White NR, et al. Antiretroviral pharmacokinetics in mothers and breastfeeding infants from 6 to 24 weeks post partum: results of the BAN study. Antivir Ther 2014; doi:10.3851/IMP2739.
12. Mirochnick M, Thomas T, Capparelli E, et al. Antiretroviral concentrations in breastfeeding infants of mothers receiving highly active antire-troviral therapy. Antimicrob Agents Chemother 2009; 53:1170-6.
13. Palombi L, Pirillo MF, Andreotti M, et al. Antiretroviral prophylaxis for breastfeeding transmission in Malawi: drug concentrations, virological efficacy and safety. Antivir Ther 2012; 17:1511-9.
14. Flynn PM, Mirochnick M, Shapiro DE, et al. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants. Antimicrob Agents Chemother 2011; 55:5914-22.
15. Hirt D, Ekouevi DK, Pruvost A, et al. Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2). Antimi-crob Agents Chemother 2011; 55:2961-7.
16. Benaboud S, Pruvost A, Coffie PA, et al. Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d'Ivoire, in the ANRS 12109 TEmAA study, step 2. Antimicrob Agents Chemother 2011; 55:1315-7.
17. Tanrantal AF, Castillo A, Ekert JE, Bischofberger N, Martin RB. Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys. J Acquir Immune Defic Syndr 2002; 29:207-20.
18. Van Rompay KK, Durand-Gasselin L, Brignolo LL, et al. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother 2008; 52:3144-60.
19. Kinai E, Hosokawa S, Gomibuchi H, Gatanaga H, Kikuchi Y, Oka S. Blunted fetal growth by tenofovir in late pregnancy. AIDS 2012; 26:2119-20.
20. Vigano A, Mora S, Giacomet V, et al. In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers. Antivir Ther 2011; 16:1259-66.
21. Ransom CE, Huo Y, Patel K, et al. Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy. J Acquir Immune Defic Syndr 2013; 64:374-81.
22. Gibb DM, Kizito H, Russell EC, et al. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. PLoS Med 2012; 9:15.
23. Wang L, Kourtis AP, Ellington S, Legardy-Williams J, Bulterys M. Safety of tenofovir during pregnancy for the mother and fetus: a systematic review. Clin Infect Dis 2013; 57:1773-81.
24. Siberry GK, Williams PL, Mendez H, et al. Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS 2012; 26:1151-9.
25. Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 2006; 118:21.
26. Siberry GK, Jacobson DL, Kalkwarf H, et al. Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fu-marate [abstract 71]. In: 21st Conference on Retroviruses and Opportunistic Infections. Boston, MA, 3-6 March 2014.
27. Mirochnick M, Taha T, Kreitchmann R, et al. Pharmacokinetics and safe-tyof tenofovir in HIV-infected women during labor and their infants during the first week of life. J Acquir Immune Defic Syndr 2014; 65:33-41.
28. Van Rompay KK, Hamilton M, Kearney B, Bischofberger N. Pharma-cokinetics of tenofovir in breast milk of lactating rhesus macaques. Antimicrob Agents Chemother 2005; 49:2093-4.
29. Van Rompay KK, Brignolo LL, Meyer DJ, et al. Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy) propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother 2004; 48:1469-87.